News

This research, conducted at University of California, San Diego, and University of California, Davis, supports the use of dual NOX1&4 inhibitors for the treatment of liver fibrosis, such

AL-704 is a nucleotide based NS5B polymerase inhibitor also known as JNJ-54257099, by Alios Biopharma, part of the Janssen Pharmaceutical Companies. It is intended for the treatment of

The IND acceptance allows the company to start an open-label Phase I trial designed to evaluate the safety, pharmacokinetics and clinical activity of KB003 in previously treated CMML

FX006 is a new, non-opioid, sustained-release, intra-articular (IA) (within the joint) formulation of triamcinolone acetonide (TCA) designed to treat patients with moderate to severe osteoarthritis (OA) pain of

Mogamulizumab is a new, humanized mAb directed against CC chemokine receptor type 4 (CCR4). Opdivo is a PD-1 immune checkpoint inhibitor that has received approval from the US

The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared

Narcan Nasal Spray has been granted Fast Track Designation by the FDA. Narcan Nasal Spray was developed in collaboration with the National Institutes on Drug Abuse (NIDA). There

The core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical Payment Services. The CSSi LifeSciences and PRC Clinical partnership equips both

"Important goals of pharmacotherapy for ulcerative colitis are to induce and maintain remission while improving the patient’s quality of life, and, based on the results from our Phase